[144] Rapport Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Rapport Therapeutics (RAPP) Form 144 notice reports a proposed sale of common stock. The filer intends to sell 10,000 shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $143,600. The shares represent a portion of 36,497,920 shares outstanding. The securities were acquired and are to be sold on 09/08/2025 following an exercise of stock options, with cash payment recorded. The filer certifies no undisclosed material adverse information and provides the required Rule 144 representations.

Positive

• Full compliance with Rule 144 disclosure requirements including broker, dates, and acquisition details
• No other sales reported in the prior three months for the reporting person
• Clear acquisition and payment information: shares acquired by exercise of options and paid in cash on 09/08/2025

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale notice: 10,000 shares from an option exercise to be sold via Morgan Stanley; no other sales in past 3 months.

The Form 144 is procedural and discloses a single proposed sale of 10,000 common shares valued at $143,600, executed through Morgan Stanley Smith Barney LLC and to be sold on NASDAQ. The shares were acquired on the same date by exercising stock options and paid for in cash. The filing states there were no other sales by the reporting person in the prior three months and includes the required attestation about material nonpublic information. This filing alone is informational and does not present material corporate developments or financial performance data.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure that documents an insider sale; no governance breaches or unusual terms evident.

The submission meets Rule 144 disclosure elements: broker identification, number of shares, aggregate value, outstanding share count, acquisition and sale dates, and nature of acquisition (exercise of options). The filer affirms no undisclosed material adverse information. There is no indication of aggregated sales, related-party transfers, or atypical consideration that would raise governance concerns based on the information provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10000	143600.00	36497920	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2025	Exercise of Stock Options	Issuer			10000	09/08/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the RAPP Form 144 disclose?

The filing discloses a proposed sale of 10,000 common shares valued at $143,600 to be executed on 09/08/2025 via Morgan Stanley on NASDAQ.

How were the 10,000 shares acquired?

The shares were acquired on 09/08/2025 through an exercise of stock options and payment was made in cash.

Does the filing report other recent sales by the same person?

No. The section on securities sold during the past three months states Nothing to Report.

What is the outstanding share count reported?

The filing lists 36,497,920 shares outstanding for the issuer.

Which broker is handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York, NY.